Skip to content

Ossiview Normative Mobility Data Collection Protocol

Ossiview Normative Mobility Data Collection Protocol

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06310278
Enrollment
120
Registered
2024-03-15
Start date
2024-05-09
Completion date
2024-10-31
Last updated
2024-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Conductive Hearing Loss, Middle Ear

Keywords

optical coherence tomography

Brief summary

The goal of this observational study is to learn about the sound-induced vibration level of certain structures in the middle ear in the normal-hearing population. The targeted structures are part of a chain of structures responsible for conducting sound within the auditory system and so their ability to vibrate normally in response to sound is relevant to the diagnosis of conductive hearing loss. The main questions the study aims to answer are: * What are the mean and variance of the normal sound-induced vibration level at two anatomical locations, the umbo of the malleus and the tip of the incus? * Are there any significant differences in these vibrational responses associated with sex or age? Participants will have their ossicular mobility measured with an investigational medical device that sends light into the middle ear and measures the motion-induced phase shift on light reflected from the target structures when a sound stimulus is presented. Standard hearing tests including audiometry and tympanometry will also be performed to confirm the normal hearing status of participants.

Interventions

DIAGNOSTIC_TESTOssicular mobility measurement

Measurements of ossicular mobility i.e. the dynamic velocity of middle ear structures (umbo of malleus and incus at the incudostapedial joint) normalized to sound pressure incident on the tympanic membrane.

Sponsors

Audioptics Medical Incorporated
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Normal-hearing * Over the age of 18 * At least one of incus or umbo visible under otoscopic examination * Type A 226Hz tympanogram with peak static compliance occurring at pressure between -99mmH20 and +50mmH20 and peak static compliance in the range from 0.3 to 1.6 cc

Exclusion criteria

* Audiometric air conduction thresholds greater than 40 dBHL at 500 Hz, 750 Hz, 1000 Hz, 1500Hz, 2000 Hz, 3000 Hz * Audiometric air bone gap greater than 5dB at 500Hz, 750Hz, 1000Hz, 1500Hz, 2000Hz and 3000Hz * Self-reported history of ear infection in the previous 3 months * Self-reported history of middle ear surgery in the last 5 years * Self-reported history of tympanic membrane perforation within the last 5 years * Self-reported medical treatment for any ear-related disorder within the last 5 years * Evidence of perforation, tympanosclerosis, otitis externa, thickened or fibrotic eardrum, mycosis, fluid, infection or other ear abnormality under otoscopy

Design outcomes

Primary

MeasureTime frameDescription
Umbo mobilityAt study completion (6 months)Estimated mean and variance of mobility in mm/s/Pa in the normal-hearing population measured at the umbo of the malleus at 500Hz, 750Hz, 1000Hz, 1500Hz, 2000Hz and 3000Hz stimulus frequencies.
Incus mobilityAt study completion (6 months)Estimated mean and variance of mobility in mm/s/Pa in the normal-hearing population measured at the incus lateral to the incudostapedial joint at 500Hz, 750Hz, 1000Hz, 1500Hz, 2000Hz and 3000Hz stimulus frequencies.

Secondary

MeasureTime frameDescription
Dependence on age and sexAt study completion (6 months)p-values for dependence on age, sex and age-sex interaction at each stimulus frequency within two-way ANOVA.

Countries

Canada

Contacts

Primary ContactRobert Adamson, PhD
rob.adamson@audiopticsmedical.com902-497-8579
Backup ContactCathy Creaser, MSc
cathy.creaser@audiopticsmedical.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026